Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

0.9600 -0.0900 (-8.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,177,340
Open 1.020
Bid (Size) 0.9600 (22)
Ask (Size) 0.9714 (1)
Prev. Close 1.050
Today's Range 0.9250 - 1.040
52wk Range 0.9250 - 3.940
Shares Outstanding 28,277,493
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025
Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Appoints Robert E. Hoffman to Board of Directors
From Esperion Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-56.4%
-56.4%
1 Month
-39.2%
-39.2%
3 Month
-55.8%
-55.8%
6 Month
-50.3%
-50.3%
1 Year
-65.6%
-65.6%

More News

Read More
Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4
Via Stocktwits
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 4, 2025
Via Benzinga
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
From Esperion Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Esperion Announces $210 Million Convertible Debt Financing
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Upcoming Jefferies London Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
From Esperion Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Esperion Therapeutics, Inc. - Common Stock publicly traded?
Yes, Esperion Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Esperion Therapeutics, Inc. - Common Stock trade on?
Esperion Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Esperion Therapeutics, Inc. - Common Stock?
The ticker symbol for Esperion Therapeutics, Inc. - Common Stock is ESPR on the Nasdaq Stock Market
What is the current price of Esperion Therapeutics, Inc. - Common Stock?
The current price of Esperion Therapeutics, Inc. - Common Stock is 0.9600
When was Esperion Therapeutics, Inc. - Common Stock last traded?
The last trade of Esperion Therapeutics, Inc. - Common Stock was at 04/10/25 04:00 PM ET
What is the market capitalization of Esperion Therapeutics, Inc. - Common Stock?
The market capitalization of Esperion Therapeutics, Inc. - Common Stock is 27.15M
How many shares of Esperion Therapeutics, Inc. - Common Stock are outstanding?
Esperion Therapeutics, Inc. - Common Stock has 27M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.